Fig. 1 · Structure

Documents & Downloads

SB 216763

Cat. No. A10825 CAS 280744-09-4

GSK-3 inhibitor

SB 216763 is a potent and selective cell permeable ATP-competitive inhibitor of GSK3α with an IC50 value of 34 nM (similar potency for GSK3β).

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
GSK-3α 34.3 nM
GSK-3β ~34.3 nM

Cellular Effect

Cell Line Activity Value Description Reference
Fibroblast IC50 3000 nM Inhibition of human SOD1 expressed in mouse fibroblasts after 48 hrs by ELISA relative to control [PMID: 24560539]
MIA PaCa-2 IC50 25 μM Growth inhibition of human MIAPaCa2 cells after 72 hrs by MTS assay [PMID: 19338355]

SB 216763 Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of SB 216763 from 3 published references. In vitro models include J1 mESCs co-cultured with MEFs; J1 mESCs. In vivo models include male CD-1 mice.

SB 216763 In Vitro Studies

In J1 mESCs co-cultured with MEFs, SB 216763 at 10–20 µM activated the normalized luciferase readout compared with vehicle control. In J1 mESC cultures supported by mitotically inactivated MEFs, 80% of colonies treated with 15 µM and 20 µM SB 216763 were rated pluripotent-like, with significant differences from vehicle-treated cultures at passage 4 and across all treated samples from passage 5 onwards. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Luciferase reporter activation in embryonic stem cell cocultures

Cell-based study · J1 mESCs co-cultured with MEFs [1]

J1 mESCs co-cultured with MEFs received SB 216763 at 10–20 µM in LIF-free mESC medium for 24 hours. The normalized luciferase readout showed activation of 7.3- and 45-fold, respectively, compared with vehicle control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Firefly luciferase activity was normalized to Renilla luciferase activity for each sample, and then all results were normalized to the vehicle control.TOPFlash activity 7.3- and 45-fold, respectively[1]

Literature-Reported Treatment Conditions

Treatment concentration
10–20 µM
Exposure duration
24 hours
Method
in LIF-free mESC medium
Vehicle
0.1% DMSO
Co-treatment
Other interventions in this design: mitomycin C inactivated MEFs 12,000 cells/well. Compound effect isolated by the comparison: vehicle control (0.1% DMSO).
Methods and source locations

Compound reported in the paper: SB 216763

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Super TOPFlash Reporter Assay (S17, S18, S20); Results > SB-216763 Induces β-catenin Mediated-transcription in a Dose-dependent Manner (S77, S81); Figure 1 legend (S171, S173)

Firefly luciferase activity was normalized to Renilla luciferase activity for each sample, and then all results were normalized to the vehicle control.: Firefly luciferase activity was normalized to Renilla luciferase activity for each sample, and then all results were normalized to the vehicle control.; comparator: vehicle control (0.1% DMSO) — Results > SB-216763 Induces β-catenin Mediated-transcription in a Dose-dependent Manner (S81); Figure 1 legend (S173)

Pluripotent-like colonies in embryonic stem cell cultures

Cell-based study · J1 mESCs [1]

J1 mESCs cultured with mitotically inactivated MEFs received medium supplemented with SB 216763 at 10, 15 and 20 µM. At 15 µM and 20 µM, 80% of colonies were rated pluripotent-like; percentages differed significantly from vehicle-treated cultures at passage 4 and across all treated samples from passage 5 onwards.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
percentage of pluripotent-like colonies two days after each passagepercentage of pluripotent-like colonies 80% of the colonies[1]

Literature-Reported Treatment Conditions

Treatment concentration
10, 15 and 20 µM
Exposure duration
passaged in parallel every 3–4 days for over a month
Method
medium supplemented with
Vehicle
0.1% DMSO
Co-treatment
Other interventions in this design: MEFs that were mitotically inactivated using 10 µg/mL mitomycin C. Compound effect isolated by the comparison: vehicle-treated cultures.
Methods and source locations

Compound reported in the paper: SB 216763

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Cell Culture (S2, S4); Results > SB-216763 Maintains mESCs with a Pluripotent-like Morphology (S97, S98, S101); Figure 2 legend (S179, S181)

percentage of pluripotent-like colonies two days after each passage: percentage of pluripotent-like colonies two days after each passage; comparator: vehicle-treated cultures — Results > SB-216763 Maintains mESCs with a Pluripotent-like Morphology (S101); Figure 2 legend (S179, S181)

SB 216763 In Vivo Studies

In uninjured male Sprague-Dawley rats, a single i.p. injection of SB 216763 increased phosphorylation of GSK-3β on Ser9. In male CD-1 mice undergoing cocaine conditioning, SB 216763 pretreatment significantly prevented the development of cocaine-induced conditioned place preference compared with vehicle pretreatment before cocaine. [2,3]

Phosphorylation changes in uninjured rats

Animal study · Male Sprague-Dawley rats; uninjured rats; n = 3/group [2]

Uninjured male Sprague-Dawley rats received a single i.p. injection of SB 216763 at 2.5 or 5 mg/kg and were euthanized 1 hr later. Treatment increased phosphorylation of GSK-3β on Ser9.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
phosphorylation of GSK-3β on Ser9Reported result For biochemical analysis, uninjured rats were given a single i.p. injection with SB-216763 (2.5 or 5 mg/kg) and killed 1 hr later (n = 3/dose). SB-216763 increases the phosphorylation of GSK-3β on Ser9 (one-way ANOVA: F(2,6) = 8.833, p = 0.016).[2]

Conditions shared by the study groups

Route
i.p.
Treatment course
a single i.p. injection; euthanized 1 hr later
Vehicle
DMSO; 60% PEG400 and 30% distilled water
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
SB 216763 2.5 or 5.0 mg/kgvehicle (0 mg/kg)For biochemical analysis, uninjured rats were given a single i.p. injection with SB-216763 (2.5 or 5 mg/kg) and killed 1 hr later (n = 3/dose). SB-216763 increases the phosphorylation of GSK-3β on Ser9 (one-way ANOVA: F(2,6) = 8.833, p = 0.016).[2]
SB 216763 2.5 or 5.0 mg/kg
Model: Male Sprague-Dawley rats; uninjured rats; n = 3/group
Methods and source locations

Compound reported in the paper: SB 216763

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Materials (S3); Materials and Methods > Drug preparation and administration (S21, S23); Results > The GSK-3 inhibitor SB-216763 improves motor function following TBI (S135, S138); Figure 6 legend (S194)

phosphorylation of GSK-3β on Ser9: phosphorylation of GSK-3β on Ser9; comparator: vehicle (0 mg/kg) — Materials and Methods > Drug preparation and administration (S23); Results > The GSK-3 inhibitor SB-216763 improves motor function following TBI (S138)

SB 216763 2.5 or 5.0 mg/kg · Materials and Methods > Drug preparation and administration (S23); Results > The GSK-3 inhibitor SB-216763 improves motor function following TBI (S135, S138)

Cocaine-conditioned place preference following pretreatment in mice

Animal study · Male CD-1 mice (8 weeks old) [3]

Male CD-1 mice received SB 216763 at 2.5 mg/kg i.p. 5 minutes before cocaine conditioning with 10 mg/kg cocaine. Pretreatment significantly prevented the development of cocaine-induced conditioned place preference compared with vehicle pretreatment before cocaine.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
preference score (time spent on cocaine-conditioned side minus time spent on saline-conditioned side)Reported result The role of GSK3 activity in cocaine-conditioned reward was evaluated by pretreating the mice with the selective GSK3 inhibitor SB 216763 (2.5 mg/kg) prior to administration of cocaine (10 mg/kg) in the conditioned place preference procedure. Pretreatment of mice with SB 216763 significantly prevented the development of cocaine-induced conditioned place preference as compared to mice pretreated[3]

Conditions shared by the study groups

Route
i.p.
Treatment course
5 minutes prior to cocaine conditioning
Vehicle
propylene glycol and brought up to volume in distilled water (70∶30)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
SB 216763 2.5 mg/kgmice pretreated with vehicleThe role of GSK3 activity in cocaine-conditioned reward was evaluated by pretreating the mice with the selective GSK3 inhibitor SB 216763 (2.5 mg/kg) prior to administration of cocaine (10 mg/kg) in the conditioned place preference procedure. Pretreatment of mice with SB 216763 significantly prevented the development of cocaine-induced conditioned place preference as compared to mice pretreated with vehicle (SB/coc vs veh/coc, **p<0.01).[3]
SB 216763 2.5 mg/kg
Model: Male CD-1 mice (8 weeks old)
Methods and source locations

Compound reported in the paper: SB 216763

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Animals (S1); Materials and Methods > Drugs (S9); Materials and Methods > Cocaine Conditioned Place Preference (S52); Results > Inhibition of GSK3 Prevented the Development of Cocaine-induced Place Preference (S112); Figure 6 legend (S153, S154, S156)

preference score (time spent on cocaine-conditioned side minus time spent on saline-conditioned side): preference score (time spent on cocaine-conditioned side minus time spent on saline-conditioned side); comparator: mice pretreated with vehicle — Results > Inhibition of GSK3 Prevented the Development of Cocaine-induced Place Preference (S112); Figure 6 legend (S154, S156)

SB 216763 2.5 mg/kg · Materials and Methods > Cocaine Conditioned Place Preference (S52); Results > Inhibition of GSK3 Prevented the Development of Cocaine-induced Place Preference (S112); Figure 6 legend (S153, S156)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 280744-09-4
Applications GSK-3 inhibitor
Formula C19H12Cl2N2O2
Molecular Weight 371.2
SMILES
CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=C(C=C(C=C4)Cl)Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 21 mg/mL (56.56 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
3 mg/mL
Vehicle
5% DMSO+corn oil

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

SB 216763 Research References

  1. [1] Kirby LA, Schott JT, Noble BL, et al. Glycogen synthase kinase 3 (GSK3) inhibitor, SB-216763, promotes pluripotency in mouse embryonic stem cells. PLoS One (2012). PMID: 22745733 DOI: 10.1371/journal.pone.0039329 Source material
  2. [2] Dash PK, Johnson D, Clark J, et al. Involvement of the glycogen synthase kinase-3 signaling pathway in TBI pathology and neurocognitive outcome. PLoS One (2011). PMID: 21935433 DOI: 10.1371/journal.pone.0024648 Source material
  3. [3] Miller JS, Barr JL, Harper LJ, et al. The GSK3 signaling pathway is activated by cocaine and is critical for cocaine conditioned reward in mice. PLoS One (2014). PMID: 24505362 DOI: 10.1371/journal.pone.0088026 Source material

Added to your cart

View Cart Checkout
Loading...